Evidence map›Paper›PMID 37406846›Full record

Trial reportAmerican journal of ophthalmology2023

Cataract Surgery in Patients With Uveitis Treated With Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: Risk Factors and Outcomes.

Douglas A Jabs, Elizabeth A Sugar, Alyce E Burke, Michael M Altaweel, James P Dunn, Sapna Gangaputra, John H Kempen, Kathryn L Pepple, Richard J Stawell, Janet T Holbrook and 1 more

Open access · greenAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Douglas A JabsFrom the Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (D.A.J., E.A.S., A.E.B., J.T.H.), Baltimore, Maryland, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine (D.A.J.), Baltimore, Maryland, USA. Electronic address: djabs@jhmi.edu.
Elizabeth A SugarFrom the Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (D.A.J., E.A.S., A.E.B., J.T.H.), Baltimore, Maryland, USA; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health (E.A.S.), Baltimore, Maryland, USA.
Alyce E BurkeFrom the Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (D.A.J., E.A.S., A.E.B., J.T.H.), Baltimore, Maryland, USA.
Michael M AltaweelSchool of Medicine and Public Health, Department of Ophthalmology and Reading Center, University of Wisconsin, Madison (M.M.A.), Madison, Wisconsin, USA.
James P DunnWills Eye Hospital, Department of Ophthalmology, Thomas Jefferson University (J.P.D.), Philadelphia, Pennsylvania, USA.
Sapna GangaputraVanderbilt Eye Institute, Vanderbilt University School of Medicine (S.G.), Nashville, Tennessee, USA.
John H KempenDepartment of Ophthalmology Harvard Medical School and Massachusetts Eye and Ear Infirmary (J.H.K.), Boston, Massachusetts, USA; MCM Eye Unit, Myung Sung Christian Medical Center General Hospital and Medical School (J.H.K.), Addis Ababa, Ethiopia.
Kathryn L PeppleDepartment of Ophthalmology, University of Washington School of Medicine (K.L.P.), Seattle, Washington, USA.
Richard J StawellDepartment of Ophthalmology, University of Melbourne, Royal Victorian Eye and Ear Hospital (R.J.S.), East Melbourne, Victoria, Australia.
Janet T HolbrookFrom the Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (D.A.J., E.A.S., A.E.B., J.T.H.), Baltimore, Maryland, USA.
Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group
Johns Hopkins University · USMassachusetts Eye and Ear Infirmary · USThe University of Melbourne · AUThomas Jefferson University · USUniversity of Washington · USUniversity of Wisconsin–Madison · USVanderbilt University · US

Funding

Multi-Center Uveitis Steriod Treatment (MUST) TrialU10EY014660 · NEI · JOHNS HOPKINS UNIVERSITY · PI HOLBROOK, JANET T. · 2004 to 2016
$33.6M
Multicenter Uveitis Steroid Treatment (MUST) TrialU10EY014655 · NEI · JOHNS HOPKINS UNIVERSITY · PI JABS, DOUGLAS A · 2004 to 2016
$4.6M
Reading Center: Multicenter Uveitis Steroid TrialU10EY014656 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI ALTAWEEL, MICHAEL M · 2004 to 2015
$2.2M
Environmental factors in the etiology of glaucomaR03EY014654 · NEI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI SCHENKMAN, JOHN B · 2004 to 2006
$431k
Leveraging long-term follow-up in the MUST Trial and Follow-up Study: Remission, Ocular outcomes and Quantifying utility in patients with severe uveitis (MUST-ROQ)R21EY029757 · NEI · JOHNS HOPKINS UNIVERSITY · PI SUGAR, ELIZABETH ANN · 2019 to 2020
$387k
NEI NIH HHS R03 EY014654NEI NIH HHS R21 EY029757NEI NIH HHS U10 EY014655NEI NIH HHS U10 EY014656NEI NIH HHS U10 EY014660
6 · The paper itself

Abstract

purposeTo evaluate the rate of, risk factors for, and outcomes of cataract surgery in patients with intermediate, posterior, and panuveitides treated with systemic corticosteroids and immunosuppression.

designCohort study of participants from a randomized clinical trial.

methodsA multicenter clinical trial with extended follow-up comprised the study setting. From the cohort of participants assigned to systemic therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study, 125 phakic eyes of 74 patients with intermediate, posterior, or panuveitides treated with systemic therapy were included. The main outcome measures were cataract surgery and visual acuity after cataract surgery.

resultsThe cumulative incidence of cataract surgery was 43% at 7 years of follow-up, and the risk did not plateau. Risk factors for cataract surgery included age >50 years (hazard ratio [HR] 2.86, 95% CI 1.52, 5.42; P = .001), topical corticosteroid use (time-updated HR 3.13, 95% CI 1.42, 6.94; P = .005), glaucoma medication use (HR 2.75, 95% CI 1.38, 5.47; P = .004), and possibly history of anterior chamber inflammation (HR 1.90, 95% CI 0.95, 3.84; P = .07). Median gain in acuity and median best corrected visual acuity 1 year after cataract surgery were 4.8 lines and 20/25, respectively, among 42 eyes undergoing cataract surgery with 1-year follow-up data.

conclusionsAmong patients with intermediate, posterior, and panuveitides, treated with oral corticosteroids and immunosuppression, there is a substantial long-term risk of cataract surgery. Visual acuity outcomes after cataract surgery are generally good.

Indexed as

CataractPanuveitisUveitisCohort StudiesFollow-Up StudiesHumansMiddle AgedRisk FactorsSteroidsSteroids

Identifiers

PMID37406846
PMCPMC10528707
OpenAlexW4382930726

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.